Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma novartis.com ↗
2020-08-22
Novartis Pharmaceuticals
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma novartis.com ↗
Evidence & citations 12 cited values
Every value below carries the sentence it was read from.
71 sources stand behind the page.
Field
Value
Cited text
Known as
spartalizumab
“This study was a first in human (FIH), open-label, Phase I-Ib/II, multi-center study which consisted of a Phase I dose escalation part of sabatolimab (MBG453) as single agent,...” NCT02608268 ↗28
“spartalizumab (PDR001), a high-affinity, ligand-blocking, humanized anti-PD-1 immunoglobulin G4 antibody, with lacnotuzumab (MCS110), a high-affinity, humanized monoclonal...” PMID 38721402 ↗May 2024
“Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” PMID 35254415 ↗Jun 2022
“A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.” PMID 32179633 ↗Mar 2020
“Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.” PMID 35217575 ↗Feb 2022
“Monoclonal antibodies, such as MBG453 and spartalizumab may interfere with the ability of tumor cells to grow and spread.” NCT03961971 ↗
“Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1).” PMID 38919826 ↗Jun 2024
ChEMBL registry synonym — accepted as the source's own labelCHEMBL4297831 ↗
Known as
Espartalizumab
ChEMBL registry synonym — accepted as the source's own labelCHEMBL4297831 ↗
Known as
NVP-LZV184
ChEMBL registry synonym — accepted as the source's own labelCHEMBL4297831 ↗
Known as
PDR001
“PDR001 (also referred to as spartalizumab) is a humanized monoclonal antibody (mAb) directed against human programmed death-1 (PD-1) that blocks the interaction between PD-1...” NCT05210413 ↗44
“This study combines canakinumab (ACZ885), a high-affinity human anti-interleukin-1β (IL-1β) monoclonal antibody (mAb), and spartalizumab (PDR001), a mAb directed against human...” NCT04581343 ↗
“Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” PMID 35254415 ↗Jun 2022
“Our prior work identified tat-βsyn-deg (PDR-001), a three-segment peptide that selectively targets α-synuclein.” NCT07157345 ↗
“We performed a proof-of-concept single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab (PDR001), dabrafenib and trametinib in 37...” PMID 36702949 ↗Jan 2023